Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Sylvie Jorieux

Christophe De Romeuf

Christine Gaucher

Emmanuel Nony

Nicolas Bihoreau

Dominique Bourel

Christian Behrens

Alexandre Fontayne

Philippe Klein

Philippe Mondon

Abdelhakim Kharrat

Khalil Bouayadi

Celine Monnet-Mars

Céline Monnet-Mars

Christine Gauchet

The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Use of ADCC-optimized antibodies for treating low-responder patients

A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Optimized FC variants

Use of ADCC-optimized antibodies for treating weak patients

The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.

Anti-rhesus D monoclonal antibody

Growing community of inventors

Villeneuve d'Ascq, France

Sylvie Jorieux